A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Adolescent
Antibodies, Bispecific
/ administration & dosage
Antineoplastic Agents
/ administration & dosage
Asian People
B-Lymphocytes
/ metabolism
Child
Drug Administration Schedule
Female
Humans
Immunotherapy
Male
Maximum Tolerated Dose
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Remission Induction
Safety
T-Lymphocytes
/ metabolism
Treatment Outcome
Acute lymphoblastic leukemia
Blinatumomab
Japan
Pediatric
Phase 1b clinical trial
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
13
08
2019
accepted:
29
05
2020
revised:
10
05
2020
pubmed:
22
6
2020
medline:
30
10
2020
entrez:
22
6
2020
Statut:
ppublish
Résumé
Novel therapies are needed for children with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is a bispecific T-cell engager immunotherapy that simultaneously binds to CD3-positive cytotoxic T cells and CD19-positive B cells and redirects the patient's T cells to lyse malignant and normal B cells. We conducted an open-label phase 1b study to determine the safety, pharmacokinetics, efficacy, and recommended dose of blinatumomab in Japanese children with R/R B-cell precursor ALL. Patients received induction blinatumomab for 4 weeks (5 μg/m
Identifiants
pubmed: 32564243
doi: 10.1007/s12185-020-02907-9
pii: 10.1007/s12185-020-02907-9
doi:
Substances chimiques
Antibodies, Bispecific
0
Antineoplastic Agents
0
blinatumomab
4FR53SIF3A
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM